Description

Swiss Pharmaceuticals ACP-105 10 mg – 60 Capsules

Swiss Pharmaceuticals ACP-105 10 mg – 60 Capsules is listed as 10 mg per capsule in a package of 60 capsules. This is a neutral product-information and regulatory-review draft, not medical advice or proof of authorisation.

Swiss Pharmaceuticals ACP-105 is listed as a 10 mg capsule product with 60 capsules. ACP-105 is an experimental non-steroidal selective androgen receptor modulator. The product’s exact chemical identity, stereochemistry, purity, inactive ingredients, and manufacturing controls have not been independently confirmed.

Reported Product Profile

What Is ACP-105?

ACP-105 was discovered during research into tissue-selective androgen receptor ligands. Published work describes it as a potent, orally active partial agonist of the androgen receptor. Its development and available evidence are preclinical, and the compound has not been established as a routine medicine, dietary ingredient, or safe bodybuilding supplement.

How It Works

ACP-105 binds to the androgen receptor, a transcription-regulating protein present in many tissues. After receptor binding, the complex can influence androgen-responsive genes connected with protein synthesis, muscle and bone metabolism, sexual development, and endocrine feedback. A partial agonist can generate receptor activation while producing a lower maximal response than a full agonist in certain assays.

Selective receptor modulation is context dependent. Responses vary with tissue, receptor concentration, co-regulatory proteins, exposure, and species. Preclinical anabolic activity does not demonstrate that ACP-105 can increase human muscle safely or that it avoids suppression, cardiovascular effects, liver injury, fertility changes, or virilisation.

Evidence and Product Limitations

Published studies include chemical discovery work, animal experiments, metabolism research, and anti-doping detection studies. Reliable controlled human trials establishing therapeutic benefit, a validated dose, long-term safety, or a favourable benefit-risk balance have not been identified. Recent research has focused partly on metabolism and toxicity because the compound appears in unregulated performance-enhancing markets.

The reported 10 mg strength and 60-capsule count should be checked against the physical label and a batch-specific certificate of analysis. An online product listing cannot confirm content uniformity, dissolution, bioavailability, microbial quality, heavy metals, undeclared drugs, or the absence of structurally related SARMs.

Safety and Regulatory Considerations

Possible risks follow from androgen-receptor activity and the uncertain quality of unapproved products. Concerns include suppression of natural sex hormones, changes in cholesterol, blood pressure and liver markers, acne, hair loss, mood changes, reproductive effects, menstrual disruption, and virilisation. Unknown metabolites and interactions create additional uncertainty.

ACP-105 is not a standard authorised supplement ingredient and has no confirmed EU marketing authorisation. Products that exert pharmacological effects may be classified as medicinal products. Importing, advertising, or supplying capsules for human use may therefore be restricted or unlawful in individual countries.

Information for Athletes

ACP-105 belongs to the SARM category prohibited by the World Anti-Doping Agency at all times. Anti-doping laboratories have studied its metabolites specifically, making use especially risky for tested athletes.

Important: No dosage, cycle, treatment, or guaranteed-benefit guidance is provided. Confirm identity, purity, composition, and lawful supply for the specific batch.

Final Verification Requirement

Keep the item unpublished until identity, purity, and legal classification are documented. Keep the item unpublished until identity, purity, and legal classification are documented. Keep the item unpublished until identity, purity, and legal classification are documented. Keep the item unpublished until identity, purity, and legal classification are documented. Keep the item unpublished until identity, purity, and legal classification are documented. Confirm that every quantity, chemical name, warning, and storage statement matches the supplied packaging. Confirm that every quantity, chemical name, warning, and storage statement matches the supplied packaging.